Latest News
-
Multibagger Energy Stock To Reward Shareholders With 3 Bonus Shares, Hits 52-Week High -
Massive Rs 33/Sh Dividend By Larsen's IT Stock, 1650% Payout Soon; LTTS Earns Profit Of Rs 341 Crore In Q4 -
Rs 7.50/Share Dividend: Adani Group Cement Company Reports Strong Q4 Results; Profit Surges 2x YoY -
Closing Bell: Market Rebounds To End With Gains For 5th Straight Day; Sensex & Nifty Soar Led By Banks -
Gold Prices Ayodhya: In Ram-Janma-Bhumi, 24carat Falls By Rs 380 In 10-Grams, Drops By Rs 3,800 In 100-gram -
Penny Stock Hits 2nd Upper Circuit After Declaring Earnings, Gains 14% In 1-Week -
Rs 8.50/Share Dividend Recommended: Nestle India Reports 27% YoY Jump In Profit -
0.50% Dividend Yield: Midcap Cement Stock Slumps 10% Following Weak Q4 Results; Profit Down 48% YoY -
1:10 Split, Rs 147/Share Dividend: FMCG Major Likely To Report Profit Growth; Buy Or Sell? -
Mark Zuckerberg's Meta Reports Record Q1 Profit Surge, Projects AI Investments This Year; Stock Slumps
Pharma Stocks Continue To Fall After Tuesday's Slide
Pharma stocks continued to fall even after witnessing a sharp slide on Tuesday. Lupin, which lost 7 per cent on Tuesday was down another half per cent. There were worries over US FDA concerns over one of the plants of the company.
After being a darling of investors though 2014 and 2015, pharma stocks have seen a sharp correction in the last few months. Worries over warnings to several companies from the US FDA have hit these stocks.
Dr Reddys, Lupin, Sun Pharma, Cadilla Health and a few others have all received adverse communication from the US FDA.
The US is a major market for exports for most of the Indian pharma companies and warning letters can hit exports.
The companies have to be very careful in adopting best manufacturing practices and also in maintainence of records.
GoodReturns.in
